KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

NCT03915405 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Termination was based on the business decision

Conditions

Urothelial Carcinoma

Interventions

DRUG: KHK2455
DRUG: Avelumab

Sponsor

Kyowa Kirin, Inc.